Photo effect on the CD1d-binding ability of azobenzene-attached analogues of α-GalCer.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 20 11 2019
revised: 28 12 2019
accepted: 04 01 2020
pubmed: 27 1 2020
medline: 22 4 2021
entrez: 27 1 2020
Statut: ppublish

Résumé

α-Galactosylceramide (α-GalCer) is recognized by the CD1d proteins on antigen-presenting cells at the ceramide moiety and the galactose moiety is presented to iNKT cells, which stimulates the immune responses. However, the immune suppression by repeated injections of α-GalCer has discouraged its development as an anti-cancer agent. To overcome the shortcoming by spatiotemporal restriction of its exposure, we synthesized the photochromic azobenzene-incorporated analogues and tested the photo-immunoregulation effect in its binding to CD1d. FACS analyses indicated that some of these analogues enhanced the affinity to CD1d on photo-irradiation by about 20%. A docking simulation suggests that the photochromic molecule should be bulkier for a clearer discrimination between on and off states.

Identifiants

pubmed: 31982233
pii: S0960-894X(20)30013-5
doi: 10.1016/j.bmcl.2020.126960
pii:
doi:

Substances chimiques

Antigens, CD1d 0
Azo Compounds 0
CD1D protein, human 0
Galactosylceramides 0
alpha-galactosylceramide 0
azobenzene F0U1H6UG5C

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126960

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Takashi Kanamori (T)

School of Life Science and Technology, Tokyo Institute of Technology, 4259 J2-10 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan.

Tomoki Numata (T)

School of Life Science and Technology, Tokyo Institute of Technology, 4259 J2-10 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan.

Satoshi Kuwabara (S)

School of Life Science and Technology, Tokyo Institute of Technology, 4259 J2-10 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan.

Yasuyuki Ishii (Y)

Department of Immunological Diagnosis, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421 Japan.

Hiroshi Watarai (H)

Department of Immunology and Stem Cell Biology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.

Hideya Yuasa (H)

School of Life Science and Technology, Tokyo Institute of Technology, 4259 J2-10 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan. Electronic address: hyuasa@bio.titech.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH